Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update

Core Insights - The company, Immunic, Inc., is advancing its lead asset, vidofludimus calcium, in the treatment of relapsing multiple sclerosis, with top-line data from Phase 3 ENSURE trials expected by the end of 2026 [1] Financial Highlights - Immunic raised $200 million in a private placement, with the potential for an additional $200 million [1] - The net proceeds from this funding are expected to support the completion of Phase 3 ENSURE trials in relapsing multiple sclerosis and initiate a Phase 3 trial in primary progressive multiple sclerosis [1] Corporate Strategy - The company is transitioning into a commercial organization as part of its growth strategy [1]